Scienture Holdings, Inc. annual report, FY2021

Business Context and Reporting Period

The supplied filing is TRxADE HEALTH, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 28, 2022. Although the request metadata names Scienture Holdings, Inc., the filing itself identifies TRxADE HEALTH, Inc. (Nasdaq: MEDS); confirm the intended issuer. This is an annual report, not a standalone fourth-quarter report.

TRxADE operates a pharmaceutical marketplace, a pharmaceutical wholesaler and a specialty pharmacy, with additional telehealth and delivery-related offerings. Marketplace revenue is generally recognized as transaction fees; wholesaling and pharmacy revenue reflect product sales. The company changed its name from Trxade Group, Inc. to TRxADE HEALTH, Inc. in June 2021.

Financial Performance and Liquidity

Revenue declined 42.2%, principally because 2020 included substantial, nonrecurring PPE sales through Integra. Marketplace revenue fell 11% to $4.92 million; Integra revenue fell to $3.25 million from $9.88 million. Higher marketplace contribution, with little associated cost of sales, lifted gross margin despite lower gross profit. The company reported $1.23 million in inventory-investment losses, including charges related to supplier deposits and unusable Bonum Health Hubs, and $1.37 million in technology, research and development expense. Bad-debt expense was $615,657, compared with $10,539 in 2020.

Year-end current assets were $4.37 million and current liabilities $0.93 million. Related-party notes payable were reduced from $225,000 to zero after repayment in 2021. Lease liabilities totaled $1.25 million, including $178,561 current and $1.07 million long term; future minimum lease payments were $1.63 million. The company reported no unused material sources of liquid assets and no off-balance-sheet arrangements. Cash used in financing was $208,178 in 2021, versus $5.30 million provided in 2020, when the company raised approximately $5.99 million in an equity offering.

Material Changes, Outlook and Risks

• Management said existing cash and expected revenue should support operations at current levels and public-company costs for the next 12 months. It estimated 2022 general and administrative and working-capital-related operating expenses at approximately $7.1 million. Expansion or acquisitions may require additional financing; no financing commitments were in place, and equity funding could dilute shareholders.
• Management plans to continue developing the Trxade platform, DelivMeds and Bonum Health and to pursue organic growth or acquisitions. DelivMeds and Bonum+ had not generated revenue; the Bonum Health Hub rollout was halted and the hubs were written down. MedCheks, which had no revenue, was discontinued and dissolved in December 2021.
• In February 2022, the company formed SOSRx, owned 51% by TRxADE and 49% by Exchange Health. TRxADE contributed $325,000 cash and issued a $500,000 non-recourse note secured by its SOSRx interest; up to $400,000 in milestone-based earn-outs may also be payable in cash or stock. The arrangement is subsequent to the reporting year.
• Two unrecovered nitrile-glove deposits, totaling $1.081 million, were written off: $500,000 involving Studebaker and $581,250 involving Crecom/Sandwave. Litigation was pending, and the company said recovery timing and amount were uncertain. A separate $630,000 receivable from GSG PPE was recorded as bad debt; related litigation was pending.
• A separate shareholder-related lawsuit settlement was reached in February 2022 for a $225,000 lump-sum payment, funded but subject to court approval. The filing says the settlement involved no admission of liability.
• The company disclosed material weaknesses in internal controls and ineffective disclosure controls as of year-end, citing manual financial consolidation and insufficient accounting and reporting personnel. Remediation was ongoing. The financial-statement auditor issued an unqualified opinion but did not audit or express an opinion on internal control effectiveness.
• Key risks include continuing losses and cash burn, dependence on suppliers and third-party contracts, pharmaceutical supply and price volatility, regulation and licensing, healthcare fraud and privacy requirements, cyber incidents, competition, possible future financing and dilution, and Nasdaq listing compliance. COVID-19-related supply, staffing and outsourcing disruptions were reported; management said they had not materially harmed results to date.

Important Facts for Investors to Verify

1. Confirm the intended issuer: the filing is for TRxADE HEALTH, Inc., not Scienture Holdings, Inc.
2. Review the audited statements and notes for cash runway, the composition of operating cash burn, inventory and bad-debt charges, and lease commitments.
3. Track progress and recoverability in the Studebaker, Crecom/Sandwave and GSG matters, including any subsequent court actions or collections.
4. Verify court approval and payment accounting for the $225,000 settlement, and assess the terms, performance and funding obligations of the SOSRx venture.
5. Assess whether internal-control remediation is completed and whether future filings report effective controls.
6. Evaluate whether management’s 12-month liquidity assessment remains supportable given losses, planned spending, potential financing needs and dilution risk.